期刊文献+

两种试剂检测抗心磷脂抗体的比较

Comparison of Two Kits in Determining Anti-Cardiolipin
下载PDF
导出
摘要 目的:对两种商品化的抗心磷脂抗体(Anti-cardiolipin,ACA)试剂的检测结果进行比较。方法采用欧蒙公司ACA-IgA/G/M(总 ACA)检测试剂和亚辉龙公司 ACA-IgG,IgM 和抗β2糖蛋白 I(β2GPI)抗体 IgG(ACA 3项)测定试剂盒,同时检测66例血清样本,比较两者结果的差异,并分析两者之间的关系。结果欧蒙总 ACA 试剂的检出阳性率为37.88%(25/66);亚辉龙 ACA 3项试剂的检出阳性率为31.82%(21/66,ACA-IgG,IgM 和抗β2GPI IgG 三者任一阳性),两种试剂检测结果不具有统计学差异;两者的检测符合率为87.88%(58/66)。欧蒙试剂 ACA-IgA/G/M 的检测结果与亚辉龙试剂 ACA-IgG,IgM 和抗β2GPI IgG 3个检测值的总和具有良好的相关性(r 2=0.892,P <0.01)。结论两种试剂检测结果符合性较高,具有良好的相关性,能满足临床应用的需要;两种试剂各具特色,可以根据需要选择合适的试剂单独或联合进行检测。 Objective To compare the results of anti-cardiolipin (ACA)measuring by two commercial available kits.Methods ACA in total of 66 serum samples were both determined by kits from Euroimmun and YHLO simultaneously,then the results were analyzed comparatively and correlatively.The Euroimmun kit was applied to determination the level of ACA-IgA/G/M,and the YHLO kit determined ACA-IgG/M and anti-β2-glycoprotein I antibody (β2GPI IgG).Results The positive rate by Euroimmun kit was 37.88% (25/66),while 31.82% (21/66)was positive (one positive among ACA-IgG,IgM andβ2GPI IgG)when determined by YHLO kit,and there was no significant difference between the two kits.The accordance rate of the two kits was 87.88% (58/66).The ACA-IgA/G/M value by Euroimmun kit and the summation of ACA-IgG, IgM andβ2GPI IgG by YHLO kit showed well linear correlation (r^ 2 =0.892,P 〈0.01).Conclusion Results from the two kits were consistent and correlated well,and they are suitable for the clinical application;these two kits have their own char-acteristics,which could be used by individual or combination accordingly.
出处 《现代检验医学杂志》 CAS 2015年第2期94-96,共3页 Journal of Modern Laboratory Medicine
关键词 抗心磷脂抗体 抗Β2糖蛋白I抗体 相关性 anti-cardiolipin anti-β2-glycoprotein I antibody association
  • 相关文献

参考文献10

  • 1Devreese KM. Antiphospholipid antibodies: evaluation of the thrombotic risk[J]. Thromb Res. 2012,130 (Suppl L) :37-40.
  • 2Meroni PL. Chighizola CB, Rovelli F. et al. Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biornarkers[J]. Arthritis Res Ther.2014,16(2) :209.
  • 3Marai 1, Gilbund B, Blank M, et al. Anti-cardiolipin and anti--2-glycoprotein I( -2GPD antibody assays as screening for anti-phospholipid syndrome [J]. Hum Antibodies. 2003.12(3) : 57-62.
  • 4Yehudai D.Toubi Ev Shoenfeld Y.et al. Autoimmunity and novel therapies in immune-mediated thrombocytopenia [J]. Semin Hernatol , 2013, 50 CSuppl 1): S100-S108.
  • 5Levy RA,de Meis Ev Pierangeli S. An adapted ELISA method for differentiating pathogenic from nonpathogenic aPL by a beta 2 glycoprotein I dependency anticardiolipin assay [J]. Thromb Res, 2004, 114 ( 5/6 ) : 573-577.
  • 6Willis R, Grossi C. Orietta Borghi M, et al. International standards for IgG and IgM anti-S 2glycoprotein antibody measurement[J]. Lupus. 2014. 23 (12): 1317-1319.
  • 7Locht H, Wiik A. IgG and IgM isotypes of anti-cardiolipin and anti-betaz-glycoprotein I antibodies reflect different forms of recent thrombo-embolic events[J]. Clin Rheumatol , 2006,25 (2) : 246-250.
  • 8刘淳,刘彦虹.抗磷脂抗体促进血栓形成机制的研究[J].现代检验医学杂志,2014,29(1):16-19. 被引量:3
  • 9张蜀澜,李永哲.抗磷脂抗体检测的现状及展望[J].中华检验医学杂志,2014,37(8):564-566. 被引量:8
  • 10张蜀澜,吴子燕,陈思,李媛,张文,李永哲.不同亚型抗磷脂抗体在系统性红斑狼疮诊断中的价值[J].中华检验医学杂志,2014,37(8):597-602. 被引量:14

二级参考文献57

  • 1Koji Habe, Hideo Wada, Takeshi Matsumoto, et al. Presence of antiphospholipid antibody is a risk factor in thrombotic events in patients with antiphospholipid syndrome or relevant diseases [J]. Int J Hematol, 2013,97(3) :345-350.
  • 2Giannakopoulos B, Passam F, Rahgozar S, et al. Cur rent concepts on the pathogenesis of the antiphospho- lipid syndrome[J]. Blood, 2007,109(2) : 422 430.
  • 3Bertolaecini ML. Antibodies to prothrombin]-J]. Lu- pus,2012,21(7) :729-731.
  • 4Vega-Ostertag M, Liu XW, Kwan-Ki H, et al. A hu- man monoelonal antiprothrombin antibody is throm bogenie in vivo and upregulates expression of tissue factor and E-selectin on endothelial cells [J]. Br J Haematol,2006,135(2) :214-219.
  • 5Deng XI.,Liu XY. Reevaluation of predictive value of ACL and anti-132GP1 antibody for thrombosis in pa- tients with systemic lupus erythematosus: from a per speetive of a practical world[J]. Rheumatol Int, 2012, 32(12) :3881 3886.
  • 6Rand JH. A new fish for the 2GPI hook:LPS[J]. Blood, 2011,117 (25) : 6743-6744.
  • 7de Laat B,Wu XX,van Lummel M,et al. Correlation between antipbospholipid antibodies that recognize domain I of beta2-glyeoprotein I and a reduction in the anticoagulant activity of annexin A5 [J]. Blood, 2007,109(4) :1490-1494.
  • 8Vlaehoyiannopoulos PG,Routsias JG. A novel mecha- nism of thrombosis in antiphospholipid antibody syn drome[J]. J Autoimmun,2010,35(3) :248-255.
  • 9Artenjak A, Lakota K,Frank M, et al. Antiphospho- lipid antibodies as non-traditional risk factors in ath- eroselerosis based cardiovascular diseases without o- vert autoimmunity. A critical updated review[J]. Au- toimmun Rev,2012,11(12) :873-882.
  • 10Sangeetha Ramesh,CrMg N Morre[1,Cristina Taran- go,et al. Antiphospholipid antibodies promote leuko cyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via heta2GPI and apoER2[J]. J Clin Invest,2011,121(1)=120-131.

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部